Source: http://www.google.co.uk/patents/US8663651
Timestamp: 2017-11-21 09:47:57
Document Index: 596623591

Matched Legal Cases: ['Application No. 60', 'Application No. 03791288', 'Application No. 03791288', 'Application No. 10176632', 'Application No. 03791288', 'Application No. 07849622', 'Application No. 07849623', 'Application No. 10176632', 'Application No. 03791288', 'Application No. 10963414', 'Application No. 10963414', 'Application No. 10963414', 'Application No. 10963414', 'Art. 79', 'Art. 94', 'Application No. 10176632', 'Art. 79', 'Art. 94', 'Application No. 10176632', 'Application No. 10789103', 'Application No. 03791288', 'Application No. 2', 'Application No. 10176632', 'Application No. 201080035931', 'Application No. 201080035931', 'Application No. 199469', 'Application No. 199468', 'Application No. 199468', 'Application No. 199469', 'Application No. 199469', 'Application No. 199468', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 199468', 'Application No. 03791288', 'Application No. 2003', 'Application No. 2', 'Application No. 03791288', 'Application No. 10963414', 'Application No. 2003', 'Application No. 10963414', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 10963414', 'Application No. 10963414', 'Application No. 2', 'Application No. 03791288', 'Application No. 03791288', 'Application No. 199468', 'Application No. 199469', 'Application No. 2', 'Application No. 01963414', 'Application No. 03791288', 'Application No. 201080035931', 'Application No. 2003', 'Application No. 2011', 'Application No. 2003', 'Application No. 201080035931']

Patent US8663651 - T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation - Google Patents
The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for immunomodulation....http://www.google.co.uk/patents/US8663651?utm_source=gb-gplus-sharePatent US8663651 - T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
Publication number US8663651 B2
Application number US 12/520,811
PCT number PCT/IL2007/001598
Filing date 23 Dec 2007
Also published as CA2673484A1, CA2673719A1, EP2094274A2, EP2094274A4, EP2104507A2, EP2104507A4, EP2759302A2, EP2759302A3, EP2942059A1, EP3011961A1, US8455450, US8765683, US20100143334, US20100166715, US20100184694, US20120207748, US20140030211, WO2008075369A2, WO2008075369A3, WO2008075370A2, WO2008075370A3, WO2008075371A2, WO2008075371A3
Publication number 12520811, 520811, PCT/2007/1598, PCT/IL/2007/001598, PCT/IL/2007/01598, PCT/IL/7/001598, PCT/IL/7/01598, PCT/IL2007/001598, PCT/IL2007/01598, PCT/IL2007001598, PCT/IL200701598, PCT/IL7/001598, PCT/IL7/01598, PCT/IL7001598, PCT/IL701598, US 8663651 B2, US 8663651B2, US-B2-8663651, US8663651 B2, US8663651B2
Inventors Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
Original Assignee Biokine Therapeutics Ltd.
Patent Citations (90), Non-Patent Citations (218), Classifications (19), Legal Events (2)
US 8663651 B2
1. A method for stimulating or enhancing in a subject in need thereof an immune response to an antigen, comprising administering to the subject: i) an immunogenic amount of the antigen, or a recombinant construct comprising a nucleic acid sequence encoding the antigen, the nucleic acid sequence being operably linked to at least one transcription control sequence, and ii) an immunogenicity-augmenting amount of a peptide as set forth in SEQ ID NO:1 in concurrent or sequential combination with said antigen.
2. The method of claim 1, wherein said antigen is selected from the group consisting of a tumor-associated antigen, a viral antigen, a bacterial antigen, a fungal antigen and a parasite-derived antigen.
This application is the U.S. national stage of PCT/IL2007/001598 filed on Dec. 23, 2007, which claims priority to and benefit of U.S. Provisional Patent Application No. 60/876,145 filed on Dec. 21, 2006, the content of each of which is expressly incorporated herein in its entirety by reference hereto.
Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 49,811 byte ASCII (text) file named “Seq_List” created on Jun. 22, 2009.
Example 2 The Chemokine MIP3α is Expressed by Prostate Xenografts that Express CXCR4 and by Primary Human Prostate Cancer Biopsies.
US4342828 15 Jul 1980 3 Aug 1982 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US5206018 29 Oct 1991 27 Apr 1993 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5250732 18 Jul 1991 5 Oct 1993 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US6365583 1 Feb 2000 2 Apr 2002 Anormed, Inc. Methods to enhance white blood cell count
US6747036 16 Jan 2002 8 Jun 2004 Biochem Pharma Inc. Methods of treating leukemia
US6875738 16 Aug 1999 5 Apr 2005 The University Of British Columbia Of Industry Liaison Office Therapeutic chemokine receptor antagonists
US7138488 5 Sep 2001 21 Nov 2006 Biokine Therapeutics Ltd. Polypeptides having anti-HIV activity and compositions comprising same
US7169750 5 Jun 2003 30 Jan 2007 Anormed, Inc. Methods to mobilize progenitor/stem cells
US7291631 12 Apr 2004 6 Nov 2007 Genzyme Corporation CXCR4 chemokine receptor binding compounds
US7419667 9 Mar 2005 2 Sep 2008 Morinaga Milk Industry Co. Ltd. Drug for cancer therapy
US7423007 26 Aug 2003 9 Sep 2008 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
US7595298 1 Aug 2006 29 Sep 2009 Biokine Therapeutics Ltd. Polypeptides having anti-HIV activity and compositions comprising same
US8017585 11 Jul 2008 13 Sep 2011 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
US20020156034 9 May 2001 24 Oct 2002 Tudan Christopher R. CXCR4 antagonist treatment of hematopoietic cells
US20020159996 5 Nov 2001 31 Oct 2002 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20040116655 * 5 Sep 2001 17 Jun 2004 Nobutaka Fujii Novel polypeptides and anti-hiv drugs containing the same
US20040209921 12 Apr 2004 21 Oct 2004 Gary Bridger CXCR4 chemokine receptor binding comounds
US20050002939 16 Dec 2003 6 Jan 2005 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
US20050043367 5 Jun 2003 24 Feb 2005 Gary Bridger Methods to mobilize progenitor/stem cells
US20060008465 11 Aug 2005 12 Jan 2006 Pharmexa A/S Novel methods for therapeutic vaccination
US20060079492 23 Sep 2005 13 Apr 2006 Ahlem Clarence N Compositions and treatment methods
US20060264378 26 Aug 2003 23 Nov 2006 Takeda Pharmaceutical Company Limited Cxcr4 antagonist and use thereof
US20060264605 1 Aug 2006 23 Nov 2006 Biokine Therapeutics Ltd. Polypeptides having anti-HIV activity and compositions comprising same
US20070167459 9 Dec 2003 19 Jul 2007 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
US20090181897 11 Jul 2008 16 Jul 2009 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
US20100143334 23 Dec 2007 10 Jun 2010 Amnon Peled T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
US20100166715 23 Dec 2007 1 Jul 2010 Amnon Peled T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
US20100184694 23 Dec 2007 22 Jul 2010 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
US20100222256 25 Aug 2009 2 Sep 2010 Nobutaka Fujii Novel polypeptide anti-HIV agent containing the same
US20110269686 8 Jul 2011 3 Nov 2011 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
US20120094907 13 Jun 2010 19 Apr 2012 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
US20120207748 29 Jan 2012 16 Aug 2012 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
CA1297007C 15 Jul 1987 10 Mar 1992 Minoru Machida Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
EP0169566A1 25 Jul 1985 29 Jan 1986 Chugai Seiyaku Kabushiki Kaisha Novel CSF and method for obtaining the same
EP0215126A1 7 Feb 1986 25 Mar 1987 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
EP0217404A2 3 Oct 1986 8 Apr 1987 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing a human granulocyte colony stimulating factor for the treatment of leukopenia
EP0220520A1 30 Sep 1986 6 May 1987 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
EP0230980A2 21 Jan 1987 5 Aug 1987 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agent for promoting the recovery of hemopoietic capacity
EP0231819A2 21 Jan 1987 12 Aug 1987 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agent for the treatment of myelogenous leukemia
EP0237545A1 22 Aug 1986 23 Sep 1987 Kirin Amgen Inc Production of pluripotent granulocyte colony-stimulating factor.
EP0243153A2 22 Apr 1987 28 Oct 1987 Immunex Corporation Human G-CSF protein expression
EP0263490A2 6 Oct 1987 13 Apr 1988 Chugai Seiyaku Kabushiki Kaisha Sustained-release particulate preparation and process for preparing the same
EP0272703A1 23 Dec 1987 29 Jun 1988 Kyowa Hakko Kogyo Co., Ltd. Novel polypeptide
EP0331186A2 3 Mar 1989 6 Sep 1989 Kyowa Hakko Kogyo Co., Ltd. Monoclonal antibody selectively binding to novel g-csf derivative
EP0335423A2 31 Mar 1989 4 Oct 1989 Kyowa Hakko Kogyo Co., Ltd. Modified human G-CSF
EP0344796A2 2 Jun 1989 6 Dec 1989 Chugai Seiyaku Kabushiki Kaisha Crystalline human granulocyte colony stimulating factor and process for preparing the same
EP0355811A2 23 Aug 1989 28 Feb 1990 Chugai Seiyaku Kabushiki Kaisha Thrombus control agent
EP0370205A2 28 Sep 1989 30 May 1990 Kyowa Hakko Kogyo Co., Ltd. Glycosylated polypeptides
EP0373679A2 18 Dec 1989 20 Jun 1990 Amgen Inc. Stabilized hydrophobic protein formulations
EP0396158A1 22 Aug 1986 7 Nov 1990 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0401384A1 22 Dec 1989 12 Dec 1990 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
EP0459516A1 31 May 1991 4 Dec 1991 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
EP0459630A2 29 Apr 1991 4 Dec 1991 Zeneca Limited Polypeptides
EP0459795A1 30 May 1991 4 Dec 1991 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
EP0473268A2 16 Jul 1991 4 Mar 1992 Zeneca Limited Continuous release pharmaceutical compositions comprising a polypeptide covalently conjugated to a water soluble polymer
EP1323730A1 5 Sep 2001 2 Jul 2003 Seikagaku Corporation Novel polypeptides and anti-hiv drugs containing the same
EP2058395A1 3 Aug 2007 13 May 2009 Kurume University Kif-derived peptide capable of binding to hla-a24 molecule
JP2002247843A Title not available
JP2002506830A Title not available
WO1991007988A1 29 Nov 1990 13 Jun 1991 Amgen Inc. Megakaryocyte production
WO1993015211A1 28 Jan 1993 5 Aug 1993 Rhone-Poulenc Rorer S.A. New polypeptides having granulocyte colony stimulating activity, preparation thereof and pharmaceutical compositions containing said polypeptides
WO1995010534A1 12 Oct 1994 20 Apr 1995 Seikagaku Corporation Polypeptide and anti-hiv agent prepared therefrom
WO1999047158A2 12 Mar 1999 23 Sep 1999 The University Of British Columbia Therapeutic chemokine receptor antagonists
WO2000006086A2 29 Jul 1999 10 Feb 2000 The Trustees Of Columbia University In The City Of New York Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
WO2000009152A1 16 Aug 1999 24 Feb 2000 The University Of British Columbia Therapeutic chemokine receptor antagonists
WO2001038352A2 15 Nov 2000 31 May 2001 Schering Corporation Methods of inhibiting metastasis
WO2001064716A1 2 Mar 2001 7 Sep 2001 Nobutaka Fujii Antiviral compounds
WO2001085196A2 9 May 2001 15 Nov 2001 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2002020561A1 5 Sep 2001 14 Mar 2002 Seikagaku Corporation Novel polypeptides and anti-hiv drugs containing the same
WO2004020462A1 26 Aug 2003 11 Mar 2004 Fujii, Nobutaka Cxcr4 antagonist and use thereof
WO2004024178A1 1 Sep 2003 25 Mar 2004 Jan Andreas Burger Cxcr4 receptor antagonists
WO2004087068A2 26 Mar 2004 14 Oct 2004 Emory University Cxcr4 antagonists and methods of their use
WO2008017025A2 * 2 Aug 2007 7 Feb 2008 Genzyme Corporation Combination therapy
WO2008075369A2 23 Dec 2007 26 Jun 2008 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
WO2008075370A2 23 Dec 2007 26 Jun 2008 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
WO2008075371A2 23 Dec 2007 26 Jun 2008 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
WO2010146578A2 13 Jun 2010 23 Dec 2010 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
WO2010146584A1 15 Jun 2010 23 Dec 2010 Biokine Therapeutics Ltd. Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
WO2012095849A1 10 Jan 2012 19 Jul 2012 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
WO2013160895A1 24 Apr 2013 31 Oct 2013 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
1 AACR "97th Annual Meeting 2006: Publications", AACR, American Association fo Cancer Research, Retreived From the Internet, 2006.
2 Abraham et al. "Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F-Benzoyl-TN14003", Stem Cells, XP002629045, 25(9): 2158-2166, May 24, 2007.
3 Advisory Action Before the Filing of an Appeal Brief Dated Nov. 16, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/520,699.
4 Amendment Dated May 15, 2008 After Notice of Allowance of Apr. 14, 2008 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/525,838.
5 Arakaki et al. "T134, A Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance With AMD3100, a CXCR4 Antagonist With a Different Structure", Journal of Virology, XP002199036, 73(2): 1719-1723, Feb. 1999.
6 Auerbach et al. "Angiogenesis Assays: Problems, Pitfalls and Potential", Cancer and Metastasis Reviews, 19: 167-172, 2000.
7 Avniel et al. "Involvement of the CXCL12/CXCR4 Pathway in the Recovery of Skin Following Burns", Journal of Investigative Dermatology, 126(2): 468-476, 2006.
8 Balkwill "The Significance of Cancer Cell Expression of the Chemokine Receptor CXCR4", Seminars in Cancer Biology, 14: 171-179, 2004.
9 Bork "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome Research, 10: 398-400, 2000.
10 Brenner "Errors in Genome Annotation", Trends in Genetics, TIG, 15(4): 132-133, Apr. 1999.
11 Broxmeyer et al. "Rapid Mobilization of Murine and Human Hematopoietic Stem and Progenitor Cells With AMD3100, A CXCR4 Antagonist", The Journal of Experimental Medicine, 201(8): 1307-1318, Apr. 18, 2005.
12 Burger et al. "CXCR4 Chemokine Receptor Antagonists: Perspectives in SCLC", Expert Opinion on Investigational Drugs, XP002711650, 18(4): 481-490, Apr. 2009.
13 Burger et al. "Potential of CXCR4 Antagonists for the Treatment of Metastatic Lung Cancer", Expert Reviews of Anticancer Therapy, XP009152669, 1(4): 621-630, Apr. 1, 2011.
14 Burger et al. "Small Peptide Inhibitors of the CXCR4 Chemokine Receptor (CD184) Antagonize the Activation, Migration, and Antiapoptotic Responses of CXCL12 in Chronic Lymphocytic Leukemia B Cells", Blood, 106(5): 1824-1830, Sep. 1, 2005.
15 Communication Pursuant to Article 94(3) EPC Dated Apr. 9, 2008 From the European Patent Office Re. Application No. 03791288.8.
16 Communication Pursuant to Article 94(3) EPC Dated Dec. 15, 2008 From the European Patent Office Re. Application No. 03791288.8.
17 Communication Pursuant to Article 94(3) EPC Dated May 3, 2013 From the European Patent Office Re. Application No. 10176632.7.
18 Communication Pursuant to Article 94(3) EPC Dated Oct. 4, 2010 From the European Patent Office Re. Application No. 03791288.8.
19 Communication Pursuant to Article 94(3) EPC Dated Oct. 4, 2013 From the European Patent Office Re. Application No. 07849622.1.
20 Communication Pursuant to Article 94(3) EPC Dated Oct. 4, 2013 From the European Patent Office Re. Application No. 07849623.9.
21 Communication Pursuant to Article 94(3) EPC Dated Sep. 11, 2013 From the European Patent Office Re. Application No. 10176632.7.
22 Communication Pursuant to Article 94(3) EPC Dated Sep. 15, 2009 From the European Patent Office Re. Application No. 03791288.8.
23 Communication Pursuant to Article 96(2) EPC Dated Feb. 6, 2006 From the European Patent Office Re. Application No. 10963414.6.
24 Communication Pursuant to Article 96(2) EPC Dated Jul. 18, 2006 From the European Patent Office Re. Application No. 10963414.6.
25 Communication Pursuant to Article 96(2) EPC Dated Jul. 26, 2007 From the European Patent Office Re. Application No. 10963414.6.
26 Communication Pursuant to Article 96(2) EPC Dated Mar. 17, 2005 From the European Patent Office Re. Application No. 10963414.6.
27 Communication Pursuant to Rule 69 EPC-Reminder Concerning Payment of the Designation Fee (Art. 79(2) EPC) and of the Examination Fee (Art. 94(1) Epc)-and Invitation Pursuant to Rule 70a(1) EPC Dated Mar. 12, 2012 From the European Patent Office Re. Application No. 10176632.7.
28 Communication Pursuant to Rule 69 EPC—Reminder Concerning Payment of the Designation Fee (Art. 79(2) EPC) and of the Examination Fee (Art. 94(1) Epc)—and Invitation Pursuant to Rule 70a(1) EPC Dated Mar. 12, 2012 From the European Patent Office Re. Application No. 10176632.7.
29 Communication Pursuant to Rules 70(2) and 70a(2) EPC Dated Jan. 22, 2013 From the European Patent Office Re. Application No. 10789103.8.
30 Communication Under Rule 71(3) EPC Dated Apr. 16, 2012 From the European Patent Office Re. Application No. 03791288.8.
31 Completion Requirement Letter Dated Oct. 24, 2013 From the Canadian Intellectual Property Office Re. Application No. 2,765,345.
32 Dar et al. "Chemokine Receptor CXCR4-Dependent Internalization and Resecretion of Functional Chemokine SDF-1 by Bone Marrow Endothelial and Stromal Cells", Nature Immunology, 6(10): 1038-1046, Oct. 2005.
33 Darash-Yahana et al. "Role of High Expression Levels of CXCR4 in Tumor Growth, Vascularization, and Metastasis", The FASEB Journal, 18: 1240-1242, 2004.
34 Di Cesare et al. "In Vitro Characterization and Inhibition of the CXCR4/CXCL12 Chemokine Axis in Human Uveal Melanoma Cell Lines", Cancer Cell International, XP021036445, 7(17): 1-8, Nov. 14, 2007. Abstract, Last Para, Title, p. 5, Right Col., Last Para.
35 Doerks et al. "Protein Annotation: Detective Work for Function Predicition", Trends in Genetics, 14(6): 248-250, Jun. 1998.
36 Esler et al. "Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial): A Randomised Controlled Trial", The Lancet, 376: 1903-1909, Published Online Nov. 17, 2010.
37 European Search Report and the European Search Opinion Dated Feb. 3, 2012 From the European Patent Office Re. Application No. 10176632.7.
38 Flomenberg et al. "The Use of AMD3100 Plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization Is Superior to G-CSF Alone", Blood, 106(5): 1867-1874, 2005.
39 Fransen et al. "Suppression of Dualtropic Human Immunodeficiency Virus Type 1 by the CXCR4 Antagonist AMD3100 Is Associated With Efficiency of CXCR4 Use and Baseline Virus Composition", Antimicrobial Agents and Chemotherapy, 52(7): 2608-2615, Apr. 28, 2008.
40 Fujii et al. "Peptide-Lead CXCR4 Antagonists With High Anti-HIV Activity", Current Opinion in Investigational Drugs, 2(9): 1198-1202, 2001.
41 Ghobrial et al. "Molecular Mechanisms Involved in Homing and Migration of Plasma Cells in Response to CXCR4", Blood, XP002629051, 104(11): 1-33, Apr. 12, 2005.
42 Gotoh et al. "Increase of R5 HIV-1 Infection and CCR5 Expression in T Cells Treated With High Concentrations of CXCR4 Antagonists and SDF-1", Journal of Infection and Chemotherapy, 7(1): 28-36, 2001.
43 Gura "Cancer Models: Systems for Identifying New Drugs Are Often Faulty", Science, 278(5340): 1041-1042, Nov. 7, 1997.
44 Hatse et al. "CXC-ChemokineReceptor 4 as a Potential New Therapeutic Target for Neuroblastoma and Breast Cancer", International Journal of Cancer, XP001156644, Supplement, 13: 349, Abstract # p. 669, Jul. 2002.
45 Hendrix et al. "Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, A Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection", Journal of Aquired Immune Deficiency Syndromes, JAIDS, 37(2): 1253-1261, Oct. 1, 2004.
46 Heredia et al. "Rapamycin Causes Down-Regulation of CCR5 and Accumulation of Anti-HIV Beta-Chemokines: An Approach to Suppress R5 Strains of HIV-1", Proc. Natl. Acad. Sci. USA, PNAS, 100(18): 10411-10416, Sep. 2, 2003.
47 Hesselgesser et al. "Neuronal Apoptosis Induced by HIV-1 Gp120 and the Chemokine SDF-1Alpha Is Mediated by the Chemokine Receptor CXCR4", Current Biology, 8: 595-598, Apr. 27, 1998.
48 Hiramatsu et al. "Synthesis of CXCR4 Antagonists, T140 Derivatives With Improved Biostability, and Their SAR Study", Peptide Science, XP009092185, 203: 213-216, 2002. Abstract, Fig. 1.
49 HIV "Report of the Investigation for Development of HIV Medicaments (Year 2000)" p. 16-21, 2001. Japanese Only!
50 HIV "Strategic Generation of Anti-AIDS Agents Based on HIV Secondary Receptor Antagonists and Modification of the Agents for Pharmaceutical Use", Report of the Investigation for Development of HIV Medicaments (Year 2000), p. 16-21, 2001. English Translation.
51 International Preliminary Report on Patentability Dated Apr. 19, 2002 From the International Preliminary Examining Authority Re. PCT/JP2001/007668.
52 International Preliminary Report on Patentability Dated Aug. 19, 2004 From the International Preliminary Examining Authority Re. Application No. PCT/JP2003/010753.
53 International Preliminary Report on Patentability Dated Dec. 29, 2011 From the International Bureau of WIPO Re. Application No. PCT/IL2010/000466.
54 International Preliminary Report on Patentability Dated Jul. 18, 2013 From the International Bureau of WIPO Re. Application No. PCT/IL2012/050008.
55 International Preliminary Report on Patentability Dated Jun. 24, 2009 From the International Bureau of WIPO Re. Application No. PCT/IL2007/001596.
56 International Preliminary Report on Patentability Dated Jun. 24, 2009 From the International Bureau of WIPO Re. Application No. PCT/IL2007/001598.
57 International Search Report and the Written Opinion Dated Dec. 5, 2008 From the International Searching Authority Re. Application No. PCT/IL2007/001596.
58 International Search Report and the Written Opinion Dated Jun. 24, 2009 From the International Searching Authority Re. Application No. PCT/IL2007/001597.
59 International Search Report and the Written Opinion Dated Jun. 4, 2008 From the International Searching Authority Re. Application No. PCT/IL2007/001598.
60 International Search Report and the Written Opinion Dated May 30, 2012 From the International Searching Authority Re. Application No. PCT/IL2012/050008.
61 International Search Report and the Written Opinion Dated Oct. 15, 2010 From the International Searching Authority Re. Application No. PCT/IL2010/000466.
62 International Search Report and the Written Opinion Dated Sep. 2, 2013 From the International Searching Authority Re. Application No. PCT/IL2013/050352.
63 International Search Report Dated Dec. 11, 2001 From the International Searching Authority Re. Application No. PCT/JP2001/007668.
64 International Search Report Dated Nov. 4, 2003 From the International Searching Authority Re. Application No. PCT/JP2003/010753.
65 Interview Summary Dated Feb. 21, 2006 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/363,209.
66 Interview Summary Dated May 3, 2005 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/363,209.
67 Jain "Barriers to Drug Delivery in Solid Tumors. Many Tumors Resist Full Penetration by Anticancer Agents. Such Resistance May Help Explain Why Drugs That Eradicate Tumor Cells in Laboratory Dishes Often Fail to Eliminate Malignancies in the Body", Scientific American, p. 58-65, Jul. 1994.
68 Kim et al. "In Vitro Behavior of Hematopoietic Progenitor Cells Under the Influence of Chemoattractants: Stromal Cell-DErived Factor-1, Steel Factor, and the Bone Marrow Environment", Blood, 91(1): 100-110, 1998.
69 Kollet et al. "Human CD34+CXCR4-Sorted Cells Harbor Intracellular CXCR4, Which Can Be Functionally Expressed and Provide NOD/SCID Repopulation", Blood, 100(8): 2778-2786, 2002.
70 Koshiba et al. "Expression of Stromal Cell-Derived Factor 1 and CXCR4 Ligand Receptor System in Pancreatic Cancer: a Possible Role for Tumor Progression", Clinical Cancer Research, 6(9): 3530-3535, Sep. 2000.
71 Kucia et al. "Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF-1-CXCR4 Axis", Stem Cells, 23(7): 879-894, Aug. 2005.
72 Kucia et al. "Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF-1—CXCR4 Axis", Stem Cells, 23(7): 879-894, Aug. 2005.
73 Lack et al. "A Pharmacokinetic-Pharmacodynamic Model for the Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100", Clinical Pharmacology and Therapeutics, 77(5): 427-436, 2005.
74 Lapidot et al. "How Do Stem Cells Find Their Way Home?", Blood, 106(6): 1901-1910, 2005.
75 Lapidot et al. "The Essential Roles of the Chemokine SDF-1 and Its Receptor CXCR4 in Human Stem Cell Homing and Repopulation of Transplanted Immune-Deficient NOD/SCID and NOD/SCID/B2m Mice", Leukemia, 16(10): 1992-2003, 2002.
76 Lapidot et al. "The Essential Roles of the Chemokine SDF-1 and Its Receptor CXCR4 in Human Stem Cell Homing and Repopulation of Transplanted Immune-Deficient NOD/SCID and NOD/SCID/B2m<Null> Mice", Leukemia, 16(10): 1992-2003, 2002.
77 Levesque et al. "Disruption of the CXCR4/CXCL12 Chemotactic Interaction During Hematopoietic Stem Cell Mobilization Induced by GCSF or Cyclophosphamide", Journal of Clinical Investigation, 111(2): 187-196, Jan. 2003.
78 Martin et al. "Chemokines Acting Via CXCR2 and CXCR4 Control the Release of Neutrophils From the Bone Marrow and Their Return Following Senescence", Immunity, 19(4): 583-593, Oct. 2003.
79 Matthys et al. "AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-Gamma Receptor-Deficient Mice", The Journal of Immunology, 167(8): 4686-4692, 2001.
80 Menu et al. "The Involvement of Stromal Derived Factor lAlpha in Homing and Progression of Multiple Myeloma in the 5TMM Model", Haematologica/the Hematology Journal, 91(5): 605-612, 2006.
81 Merck "Clinical Aspects of Cancer", The Merck Manual, Jun. 26, 2007.
82 Merck "Introduction: Overview of Cancer", The Merck Manual, Jun. 26, 2007.
83 Merck "Rheumatoid Arthritis (RA)", The Merck Manual, 18th Ed., 2005.
84 Mori et al. "Involvement of Stromal Cell-Derived Factor 1 and CXCR4 Receptor System in Pancreatic Cancer", Gastroenterology, XP009021758, 122(4/Suppl.1): A490, Abstract # T1608, Apr. 2002.
85 Mueller et al. "Involvement of Chemokine Receptors in Breast Cancer Metastasis", Nature, 410: 50-56, Mar. 2001.
86 Nagasawa et al. "Molecular Cloning and Structure of a Pre-B-Cell Growth-Stimulating Factor", Proc. Natl. Acad. sci. USA, 91: 2305-2309, Mar. 1994.
87 Nakashima et al. "Anti-Human Immunodeficiency Virus Activity of a Novel Synthetic Peptide, T22 ([Tyr-5,12, Lys-7]Polyphemusin II): A Possible Inhibitor of Virus-Cell Fusion", Antimicrobial Agents and Chemotherapy, 36(6): 1249-1255, Jun. 1992.
88 Neidl "Failure Modes in the Discovery Process", Cancer Drug Design and Discovery, Chap.18.2.2: 427-431, 2008.
89 Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", The Protein Folding Problem and Tertiary Structure Prediction, Chap.14: 433-440, 492-495, 1994.
90 Notice of Allowance Dated Apr. 11, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/172,007.
91 Notice of Allowance Dated Apr. 14, 2008 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/525,838.
92 Notice of Allowance Dated Dec. 10, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/178,737.
93 Notice of Allowance Dated Feb. 8, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/520,699.
94 Notice of Allowance Dated Jan. 4, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/583,746.
95 Notice of Allowance Dated Mar. 9, 2006 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/363,209.
96 Notice of Allowance DAted May 21, 2009 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/497,225.
97 Notification of Office Action and Search Report Dated Mar. 6, 2013 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201080035931.5 and Its Summary in English.
98 Notification of Office Action and Search Report Dated Nov. 5, 2013 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201080035931.5 and Its Translation into English.
99 Office Action Dated Jul. 28, 2013 From the Israel Patent Office Re. Application No. 199469 and Its Translation Into English.
100 Office Action Dated Mar. 13, 2013 From the Israel Patent Office Re. Application No. 199468 and Its Translation Into English.
101 Office Action Dated May 4, 2010 From the Israel Patent Office Re. Application No. 199468.
102 Office Action Dated May 4, 2010 From the Israel Patent Office Re. Application No. 199469.
103 Office Action Dated Oct. 31, 2011 From the Israel Patent Office Re. Application No. 199469 and Its Translation Into English.
104 Office Action Dated Sep. 4, 2011 From the Israel Patent Office Re. Application No. 199468 and Its Translation Into English.
105 Official Action Dated Apr. 24, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/360,751.
106 Official Action Dated Aug. 28, 2008 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/497,225.
107 Official Action Dated Dec. 28, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/583,746.
108 Official Action Dated Dec. 7, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/520,699.
109 Official Action Dated Jan. 24, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/172,007.
110 Official Action Dated Jan. 29, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/360,751.
111 Official Action Dated Jul. 1, 2010 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/172,007.
112 Official Action Dated Jul. 11, 2007 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/525,838.
113 Official Action Dated Jun. 15, 2005 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/363,209.
114 Official Action Dated Mar. 5, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/520,803.
115 Official Action Dated May 18, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/178,737.
116 Official Action Dated May 4, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/520,699.
117 Official Action Dated May 6, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/360,751.
118 Official Action Dated Nov. 3, 2005 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/363,209.
119 Official Action Dated Sep. 10, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/583,746.
120 Official Action Dated Sep. 12, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/520,803.
121 Official Action Dated Sep. 5, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/520,699.
122 Omagari et al. "Development of Specific CXCR4 Inhibitors Based on an Anti-HIV Peptide, T140, and Their Structure-Activity Relationships Study", Peptide Science, 2000(37): 129-132, 2001.
123 Peled et al. "Dependence of Human Stem Cell Engraftment and Repopulation of NOD/SCIDMice on CXCR4", Science, 283(5403): 845-848, 1999.
124 Phillips et al. "The Stromal Derived Factor-1/CXCL12-CXC Chemokine Receptor 4 Biological Axis in Non-Small Cell Lung Cancer Metastatis", 167: 1676-1686, 2003.
125 Phillips et al. "Epidermal Growth Factor and Hypoxia-Induced Expression of CXC Chemokine Receptor 4 on Non-Small Cell Lung Cancer Cells Is Regulated by the Phosphatidylinositol 3-Kinase/PTEN/AKT/Mammalian Target of Rapamycin Signaling Pathway and Activation of Hypoxia Inducible Factor-lAlpha", The Journal of Biological Chemistry, 280(23): 22473-22481, 2005.
126 Princen et al. "HIV Chemokine Receptor Inhibitors as Novel Anti-HIV Drugs", Cytokine & Growth Factor Reviews, 16(6): 659-677, 2005.
127 Ratajczak et al. "T140 Enhances G-CSF-Induced Mobilization of Hematopoietic Stem Cells", Experimental Hematology, 31: 154, Abstract #280, 2003.
128 Requisition by the Examiner Dated Aug. 25, 2009 From the Canadian Intellectual Property Office Re. Application No. 2,421,183.
129 Requisition by the Examiner Dated Jul. 4, 2013 From the Canadian Intellectual Property Office Re. Application No. 2,537,158.
130 Requisition by the Examiner Dated Jul. 6, 2012 From the Canadian Intellectual Property Office Re. Application No. 2,421,183.
131 Requisition by the Examiner Dated Jul. 8, 2013 From the Canadian Intellectual Property Office Re. Application No. 2,421,183.
132 Requisition by the Examiner Dated Jun. 18, 2013 From the Canadian Intellectual Property Office Re. Application No. 2,673,484.
133 Requisition by the Examiner Dated Mar. 8, 2011 From the Canadian Intellectual Property Office Re. Application No. 2,421,183.
134 Requisition by the Examiner Dated May 19, 2011 From the Canadian Intellectual Property Office Re. Application No. 2,421,183.
135 Requisition by the Examiner Dated May 25, 2010 From the Canadian Intellectual Property Office Re. Application No. 2,537,158.
136 Requisition by the Examiner Dated Oct. 17, 2011 From the Canadian Intellectual Property Office Re. Application No. 2,537,158.
137 Requisition-Sequence Listing Dated Jan. 5, 2011 From the Canadian Intellectual Property Office Re. Application No. 2,673,719.
138 Requisition—Sequence Listing Dated Jan. 5, 2011 From the Canadian Intellectual Property Office Re. Application No. 2,673,719.
139 Requisition-Sequence Listing Dated May 9, 2013 From the Canadian Intellectual Property Office Re. Application No. 2,673,719.
140 Requisition—Sequence Listing Dated May 9, 2013 From the Canadian Intellectual Property Office Re. Application No. 2,673,719.
141 Respone Dated Jan. 4, 2012 to Office Action of Sep. 4, 2011 From the Israel Patent Office Re. Application No. 199468 and Its Translation Into English.
142 Response Dated Apr. 15, 2009 to Communication Pursuant to Article 94(3) EPC of Dec. 15, 2008 From the European Patent Office Re. Application No. 03791288.8.
143 Response Dated Apr. 18, 2005 to Restriction Official Action of Mar. 18, 2005 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/363,209.
144 Response Dated Dec. 8, 2009 to Office Action of Aug. 11, 2009 From the Japanese Patent Office Re. Application No. 2003-301176.
145 Response Dated Feb. 24, 2010 to Requisition by the Examiner of Aug. 25, 2009 From the Canadian Intellectual Property Office Re. Application No. 2,421,183.
146 Response Dated Feb. 3, 2006 to Official Action of Nov. 3, 2005 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/363,209.
147 Response Dated Jan. 21, 2010 to Communication Pursuant to Article 94(3) EPC of Sep. 15, 2009 From the European Patent Office Re. Application No. 03791288.8.
148 Response Dated Jan. 26, 2009 to Official Action of Aug. 28, 2008 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/497,225.
149 Response Dated Jan. 29, 2007 to Communication Pursuant to Article 96(2) EPC of Jul. 18, 2006 From the European Patent Office Re. Application No. 10963414.6.
150 Response Dated Jan. 31, 2011 to Office Action of Oct. 19, 2010 From the Japanese Patent Office Re. Application No. 2003-301176.
151 Response Dated Jan. 8, 2008 to Official Action of Jul. 11, 2007 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/525,838.
152 Response Dated Jul. 1, 2005 to Communication Pursuant to Article 96(2) EPC of Mar. 17, 2005 From the European Patent Office Re. Application No. 10963414.6.
153 Response Dated Jun. 10, 2009 to Restriction Official Action of Mar. 26, 2009 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/172,007.
154 Response Dated Jun. 30, 2010 to Requisition by the Examiner of May 19, 2011 From the Canadian Intellectual Property Office Re. Application No. 2,421,183.
155 Response Dated Jun. 4, 2008 to Restriction Official Action of Apr. 8, 2008 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/497,225.
156 Response Dated Mar. 22, 2011 to Requisition-Sequence Listing of Jan. 5, 2011 From the Canadian Intellectual Property Office Re. Application No. 2,673,719.
157 Response Dated Mar. 22, 2011 to Requisition—Sequence Listing of Jan. 5, 2011 From the Canadian Intellectual Property Office Re. Application No. 2,673,719.
158 Response Dated Mar. 23, 2011 to Official Action of Jan. 24, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/172,007.
159 Response Dated May 25, 2007 to Restriction Official Action of Feb. 6, 2007 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/525,838.
160 Response Dated May 9, 2006 to Communication Pursuant to Article 96(2) EPC of Feb. 6, 2006 From the European Patent Office Re. Application No. 10963414.6.
161 Response Dated Nov. 1, 2010 to Official Action of Jul. 1, 2010 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/172,007.
162 Response Dated Nov. 16, 2007 to Communication Pursuant to Article 96(2) EPC of Jul. 26, 2007 From the European Patent Office Re. Application No. 10963414.6.
163 Response Dated Nov. 25, 2011 to Requisition by the Examiner of May 25, 2010 From the Canadian Intellectual Property Office Re. Application No. 2,537,158.
164 Response Dated Oct. 12, 2010 to Communication Pursuant to Article 94(3) EPC of Oct. 4, 2010 From the European Patent Office Re. Application No. 03791288.8.
165 Response Dated Oct. 14, 2011 to Restriction Official Action of Sep. 14, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/583,746.
166 Response Dated Oct. 15, 2008 to Communication Pursuant to Article 94(3) EPC of Apr. 9, 2008 From the European Patent Office Re. Application No. 03791288.8.
167 Response Dated Oct. 21, 2010 to Office Action of May 4, 2010 From the Israel Patent Office Re. Application No. 199468.
168 Response Dated Oct. 21, 2010 to Office Action of May 4, 2010 From the Israel Patent Office Re. Application No. 199469.
169 Response Dated Sep. 15, 2005 to Official Action of Jun. 15, 2005 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/363,209.
170 Response Dated Sep. 7, 2011 to Requisition by the Examiner of Mar. 8, 2011 From the Canadian Intellectual Property Office Re. Application No. 2,421,183.
171 Restriction Official Action Dated Apr. 8, 2008 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/497,225.
172 Restriction Official Action Dated Dec. 28, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/520,803.
173 Restriction Official Action Dated Feb. 16, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/178,737.
174 Restriction Official Action Dated Feb. 6, 2007 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/525,838.
175 Restriction Official Action Dated Mar. 1, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/520,699.
176 Restriction Official Action Dated Mar. 18, 2005 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/363,209.
177 Restriction Official Action Dated Mar. 26, 2009 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/172,007.
178 Restriction Official Action Dated Oct. 3, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/378,061.
179 Restriction Official Action Dated Sep. 14, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/583,746.
180 Rossi et al. "The Biology of Chemokines and Their Receptors", Annual Reviews of Immunology, 18: 217-242, 2000.
181 Second Amendment Dated Jul. 14, 2008 to Amendment of May 15, 2008 After Notice of Allowance of Apr. 14, 2008 From the US Patent and Trademark Office Re. U.S. Appl. No. 10/525,838.
182 Skolnick et al. "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era", Trends in Biotechnology, TIBTECH, 18(1): 34-39, Jan. 2000.
183 Sporn et al. "Chemoprevention of Cancer", Carcinogenesis, 21(3): 525-530, 2000.
184 Su et al. "Differential Expression of CXCR4 Is Associated With the Metastatic Potential of Human Non-Small Cell Lung Cancer Cells", Clinical Cancer Research, XP055076137, 11(23): 8273-8280, Dec. 1, 2005.
185 Supplementary European Search Report Dated Nov. 19, 2004 From the European Patent Office Re. Application No. 01963414.6.
186 Supplementary Partial European Search Report Dated Nov. 28, 2007 From the European Patent Office Re. Application No. 03791288.8.
187 Tamamura "Development of Selective Antagonists Against an HIV Second Receptor", Yakugaku Zasshi, 121(11): 781-792, 2001. Abstract in English.
188 Tamamura et al. "A Low-Molecular-Weight Inhibitor Against the Chemokine Receptor CXCR4: A Strong Anti-HIV Paptide T140", Biochemical and Biophysical Research Communications, 253(3): 877-882, 1998.
189 Tamamura et al. "Development of Selective Antagonists Against an HIV Second Receptor", Yakugaku Zasshi, 121(11): 781-792, 2001. English Translation.
190 Tamamura et al. "Enhancement of the T140-Based Pharmacophores Leads to the Development of More Potent and Bio-Stable CXCR4 Antagonists", Organic Biomolecular Chemistry, 1: 3663-3669, 2003.
191 Tamamura et al. "The Therapeutic Potential of CXCR4 Antagonists in the Treatment of HIV Infection, Cancer Metastasis and Rheumatoid Arthritis", Expert Opinion of Therapeutic Targets, 9(6): 1267-1282, 2005.
192 Tamamura et al. "A Future Perspective on the Development of Chemokine Receptor CXCR4 Antagonists", Database EMBASE [Online], XP002675634, Database Accession No. EMB-2008509452, Oct. 2008. & Expert Opinion on Drug Discovery, 3(10): 1155-1166, Oct. 2008.
193 Tamamura et al. "A Low-Molecular-Weight Inhibitor Against the Chemokine Receptor CXCR4: A Strong Anti-HIV Peptide T140", Biochemic and Biophysical Research Communications, XP002169961, 253(3): 877-882, Jan. 1, 1998. Abstract, Fig.1.
194 Tamamura et al. "A Low-Molecular-Weight Inhibitor Against the Chemokine Receptor CXCR4: A Strong Anti-HIV Peptide T140", Biochemical and Biophysical Research Communications, 253(3): 877-882, 1998.
195 Tamamura et al. "Certification of the Critical Importance of L-3-(2-Naphtyl)Alanine at Position 3 of a Specific CXCR4 Inhibitor, T140, Leads to an Exploratory Performance of Its Downsizing Study", Bioorganic & Medicinal Chemistry, 10: 1417-1426, 2002.
196 Tamamura et al. "Development of Specific CXCR4 Inhibitors Possessing High Selectivity Indexes as Well as Complete Stability in Serum Based on an Anti-HIV Peptide T140", Bioorganic & Medicinal Chemistry Letters, XP002265743, 11(14): 1897-1902, Jul. 23, 2001. Abstract, Fig.1, p. 1901, r-h Col., Last Sentence Before ‘Acknowledgements’.
197 Tamamura et al. "Downsizing of an HIV-Cell Fusion Inhibitor, T22 ([Tyr5,12, Lys7]-Polyphemusin II), With the Maintenance of Anti-HIV Activity and Solution Structure", Bioorganic & Medicinal Chemistry, 6: 473-479, 1998.
198 Tamamura et al. "Downsizing of an HIV-Cell Fusion Inhibitor, T22 ([Tyr5,12, Lys7]-Polyphemusin II), With the Maintenance of Anti-HIV Activity and Solution Structure", Bioorganic & Medicinal Chemistry, XP002458598, 6(4): 473-479, Apr. 1998. Abstract, Fig.1.
199 Tamamura et al. "Effective Lowly Cytotoxic Analogs of an HIV-Cell Fusion Inhibitor, T22 ([Tyr5,12, Lys7]-Polyphemusin II)", Bioorganic & Medicinal Chemistry, 6(2): 231-238, 1998.
200 Tamamura et al. "Effective Lowly Cytotoxic Analogs of an HIV-Cell Fusion Inhibitor, T22 ([Tyr5,12, Lys7]-Polyphemusin II)", Bioorganic & Medicinal Chemistry, XP002906341, 6(2): 231-238, Jan. 1, 1998. Abstract, Fig.l.
201 Tamamura et al. "Efficient Analogs of an Anti-HIV Peptide, T22 ([Tyr5,12, Lys7]-Polyphemusin II), Having Low Cytotoxicity", Peptide Science—Present and Future, Proceedings of the 1st International Peptide Symposium, XP002973954, 1997: 427-429, Jan. 1, 1999. Abstract, Fig.2.
202 Tamamura et al. "HIV-Cell Fusion Inhibitors Targeted to the HIV Second Receptor: T22 and Its Downsized Analogs With High Activity", Peptide Science, 1998(35): 49-52, 1999.
203 Tamamura et al. "Pharmacophore Identification of a Specific CXCR4 Inhibitor, T140, Leads to Development of Effective Anti-HIV Agents With Very High Selectivity Indexes", Bioorganic & Medicinal Chemistry Letters, 10(23): 2633-2637, 2000.
204 Tamamura et al. "T140 Analogs as CXCR4 Antagonists Identified as Anti-Metastatic Agents in the Treatment of Breast Cancer", FEBS Letters, 550: 79-83, 2003.
205 Tamamura et al. "T140 Analogs as CXCR4 Antagonists Identified as Anti-Metastatic Agents in the Treatment of Breast Cancer", FEBS Letters, XP004448372, 550: 79-83, Aug. 28, 2003.
206 Translation of Notification of Office Action Dated Mar. 6, 2013 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201080035931.5.
207 Translation of Office Action Dated Aug. 11, 2009 From the Japanese Patent Office Re. Application No. 2003-301176.
208 Translation of Office Action Dated Feb. 1, 2013 From the Japanese Patent Office Re. Application No. 2011-060367.
209 Translation of Office Action Dated Oct. 19, 2010 From the Japanese Patent Office Re. Application No. 2003-301176.
210 Translation of Search Report Dated Mar. 6, 2013 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201080035931.5.
211 Tsutsumi et al. "Therapeutic Potential of the Chemokine Receptor CXCR4 Antagonists as Multifunctional Agents", Biopolymers (Peptide Science), XP002629052, 88(2): 279-289, 2006.
212 Ulvatne et al. "Short Antibacterial Peptides and Erythromycin Act Synergically Against Escherichia coli", Journal of Antimicrobial Chemotherapy, 48: 203-208, 2001.
213 Voermans et al. "Migratory Behavior of Leukemic Cells From Acute Myeloid Leukemia Patients", Leukemia, 16(4): 650-657, Apr. 2002.
214 Weekes et al. "Stromal Derived FactorlAlpha Mediates Resistance to mTOR Inhibition by the Preservation of Hypoxia Inducible Factor-!Alpha (HIF-1Alpha) Expression", Proceedings of the Annual Meeting of the American Association for Cancer Research, AACR, 47: 553, Abstract #2341, 2006.
215 Wells "Additivity of Mutational Effects in Proteins", Biochemistry, 29(37): 8509-8517, Sep. 18, 1990.
216 Zannettino et al. "Elevated Serum Levels of Stromal-Derived Factor-1Alpha Are Associated With Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients", Cancer Research, 65(5): 1700-1709, Mar. 1, 2005.
217 Zhou et al. "CXCR4 Is a Major Chemokine Receptor on Glioma Cells and Mediates Their Survival", The Journal of Biological Chemistry, 277(51): 49481-49487, Dec. 29, 2002.
218 Zuluaga et al. "Neutropenia Induced in Outbred Mice by a Simplified Low-Dose Cyclophosphamide Regimen: Characterization and Applicability to Diverse Experimental Models of Infectious Diseases", BMC Infectious Diseases, 6(55): 1-10, Mar. 17, 2006.
U.S. Classification 424/196.11, 514/19.3, 424/192.1, 514/19.2, 424/193.1, 514/21.5, 424/184.1, 514/1, 424/185.1, 514/1.1
International Classification A61K39/00, A61K39/385, A61K39/38, A01N61/00, A61K38/00, A61K31/00
Cooperative Classification A61K38/10, A61K38/193, A61K35/28
27 Aug 2017 MAFP